Work

Evaluation of Melphalan 1-Day Versus 2-Day Dosing in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Year: 2013

Type: article

Abstract: Multiple myeloma (MM) is the most common plasma cell disorder with an incidence of 4-5 new cases per 100,000 individuals per year. High dose chemotherapy with melphalan followed by autologous stem cell transplantation (SCT) is considered the standard of care. Melphalan 200 mg/m2 is considered the gold standard conditioning regimen prior to autologous SCT. The Intergroupe Francophone du Myélome randomized trial confirmed that patients receiving melphalan 200 mg/m2 displayed a better median overall survival as compared to patients treated with melphalan 140 mg/m2 in combination with total body irradiation (65 vs.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2012.11.615